Women’s health startup Biorithm is trying to revolutionize maternal care. Through mobile technology and data science, the company aims to provide pregnant women with more convenience and better pregnancy information no matter where they are. The women’s health space is expected to be worth $1 trillion by 2027, and the Singapore-based company is part of a growing femtech industry that has investors excited.
Pregnancy and childbirth are safer than ever.
According to the World Health Organization, maternal mortality fell by approximately 34% between 2000 and 2020.
However, despite this progress, a maternal death occurred almost every two minutes in 2020, and approximately 6,500 newborns died every day.
Singaporean medical technology start-up Biorithm hopes to help solve this problem through mobile technology and data science.
“Women’s healthcare has not been innovative in decades and has not met the needs of the modern woman,” said Amrish Nair, co-founder and chief technology officer of Biorithm.
“Knowing this, we can provide healthcare services to mothers at a time that is convenient for them,” Nair told CNBC Tech: The Edge.
Founded by doctors and engineers, the company has developed a maternity care platform called Femom that allows clinicians to provide care to mothers and babies anytime, anywhere.
“Biorithm’s real purpose is to end preventable adverse outcomes in pregnancy, and we hope to achieve this by improving access to care by developing remote monitoring technology that allows patients to bring the hospital to their homes,” Nair said.
Watch the video above to see how Femom works.
About The Author
